Jade Biosciences: Engaging with Investors at Conferences
Jade Biosciences, Inc. (NASDAQ: JBIO), a pioneering biotechnology firm, has announced its upcoming participation in significant investor conferences aimed at fostering dialogue about its innovative therapies for autoimmune diseases.
Highlights of Upcoming Conferences
Tom Frohlich, CEO, along with Andrew King, BVMS, Ph.D., the Chief Scientific Officer and Head of R&D, will engage in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference. This will be held on July 14, 2025, starting at 3:00 p.m. ET. Attendees can expect a live webcast available on Jade’s website's Investors & Media section, with a replay accessible for 90 days thereafter.
Following this, Mr. Frohlich and Dr. King will also participate in another fireside chat at the anticipated 2025 Stifel Biotech Summer Summit set for August 13, 2025, at 7:30 a.m. ET. This offers another excellent opportunity for investors to interact with the leaders behind Jade’s innovative approaches.
One-on-One Investor Meetings
In addition to these panels, Jade's management team will be available for one-on-one investor meetings throughout the conferences. This is an ideal chance for attendees to discuss Jade's strategic plans, potential partnerships, and the progress made with their clinical candidates.
About Jade Biosciences, Inc.
Jade Biosciences is committed to developing exceptional therapies to meet pressing needs in treating autoimmune diseases. Their leading therapeutic candidate, JADE101, focuses on the APRIL cytokine for addressing immunoglobulin A nephropathy, with the first human clinical trial planned for the latter half of 2025.
In addition to JADE101, Jade's research pipeline includes another candidate, JADE201, and an antibody discovery program, named JADE-003, currently in preclinical development. These promising therapies were developed based on assets licensed from Paragon Therapeutics, an innovator in antibody discovery founded by Fairmount.
Contact Information for Inquiries
For further inquiries or media interest regarding potential collaborations, please contact:
Priyanka Shah
Media@JadeBiosciences.com
IR@JadeBiosciences.com
908-447-6134
Frequently Asked Questions
What is Jade Biosciences known for?
Jade Biosciences develops innovative therapies targeting autoimmune diseases, with a strong focus on unmet medical needs.
When will Jade’s clinical trials begin?
The first human clinical trial for JADE101 is expected to initiate in the second half of 2025.
Who are the key figures at Jade participating in the conferences?
Tom Frohlich, CEO, and Andrew King, Chief Scientific Officer, will represent Jade at the conferences.
What are the two conferences Jade Biosciences will participate in?
Jade will engage in the H.C. Wainwright 4th Annual Kidney Virtual Conference and the 2025 Stifel Biotech Summer Summit.
How can investors connect with Jade's team?
Investors can schedule one-on-one meetings with Jade’s management team during the conferences for in-depth discussions.